Results 121 to 130 of about 39,159 (175)

Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model. [PDF]

Braz J Med Biol Res
Chege BM, Mwangi PW, Githinji CG, Bukachi F.   +3 more
europepmc   +1 more source

Prevalence of high-risk human papillomavirus genotypes and associated factors among HIV-infected women in a reproductive age group attending antiretroviral therapy in Nekemte town, Oromia, Ethiopia. [PDF]

PLoS One
Gebeyehu R, Gizaw S, Amensisa D, Bekele T, Merkeb B, Alemu F, Cewaka G.   +6 more
europepmc   +1 more source

Atazanavir/Ritonavir-Associated Erythema Multiforme in an HIV-1-Positive Patient. [PDF]

Cureus
Singh RK.
europepmc   +1 more source

Efficacy and safety of TDF+3TC + EFV‑centric antiretroviral regimens for HIV/HBV co-infection: a systematic review and network meta‑analysis. [PDF]

BMC Infect Dis
Zhang X, Chen J, Fang Y, Xie Z, Deng Y, Deng J, Zhou Z.   +6 more
europepmc   +1 more source

VOGUE: Noninferior Efficacy of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults With HIV-1 Naive to Treatment. [PDF]

Open Forum Infect Dis
Ghosn J, Pulido F, Lopardo GD, Olczak A, Ripamonti D, Martin C, Paredes Ceballos O, Stocker H, Mendez Vazquez MJ, Gatanaga H, Metallidis S, Elbirt D, Whitlock G, Mateo González JI, Mohammed P, Wang K, Grove R, Wang R, Jewell A, Sutton K, Elliot E, Moodley R, Borsi R, Jones B, Kisare M, Budnik P, van Wyk J, VOGUE Study Group, VOGUE Study Group .   +28 more
europepmc   +1 more source

Rapid Virologic Suppression With Dolutegravir Plus Lamivudine Facilitates Early Switch to Long-Acting Cabotegravir Plus Rilpivirine for Treatment-Naive People With HIV-1: Month 11/12 Outcomes From the Phase 3b VOLITION Study. [PDF]

Open Forum Infect Dis
Córdova E, Rolle CP, Hove K, Felizarta F, Johnson M, Cuevas Tascón G, Molina JM, Bravo Urbieta J, Hocqueloux L, Lupo S, Perez CM, Ole Jensen BE, Jonsson-Oldenbüttel C, Zamora Vargas FX, Szabo J, Cahn P, Antinori A, López Bernaldo de Quirós JC, Castagna A, Bui M, Grove R, Wang K, St Clair M, Moodley R, Radford J, Priest J, Gutner CA, Jacob I, Chatterjee A, Somvanshi S, Kolobova I, Trehan R, Polk C, Patel P, de Los Rios P, DiMondi P, Gordon LA, Brown K, Garges HP, Jones B, van Wyk J.   +40 more
europepmc   +1 more source

Lamivudine treatment in patients with HBV-related hepatocellular carcinoma--using an untreated, matched control cohort.

Lamivudine is widely used to treat patients with hepatitis B. However, the outcomes in patients with hepatocellular carcinoma (HCC) treated with lamivudine have not been established.
Araki, Yasuyuki, Shiratori, Yasushi, Sakaguchi, Kohsaku, Piao, Cheng-Yu, Senoh, Tomonori, Kobashi, Haruhiko, Kaneyoshi, Toshihiko, Iwasaki, Yoshiaki, Fujio, Kozo, Terada, Ryo, Hashimoto, Kuniaki, Fujioka, Shin-ichi, Nishida, Tomohiro   +12 more
core  

A novel design using a virtual control group to evaluate non-inferiority of nevirapine and lamivudine dual maintenance in HIV therapy. [PDF]

PLoS One
Suter A, Bickel M, Depmeier C, Gute P, Knecht G, Stöckle M, Fux C, Flury BB, Schmid P, Vernazza P, Kahlert CR.   +10 more
europepmc   +1 more source

'Leaving no stones unturned': up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort. [PDF]

J Antimicrob Chemother
Ciccullo A, Baldin G, Cervo A, Oreni L, Mazzitelli M, Gasparro G, Menozzi M, Cesaretti M, Bassani F, Lagi F, Lombardi F, Giacomelli A, Borghetti A, Fabbiani M, Rusconi S, Cattelan A, Antinori S, Mussini C, Di Giambenedetto S.   +18 more
europepmc   +1 more source

Lamivudine resistance in untreated chronic hepatitis B patients in Turkey

The Turkish Journal of Gastroenterology, 2008
Semra TUNÇBİLEK, Şükran KÖSE, Ahmet ELALDI, Sezin AKMAN   +3 more
doaj